The University of Chicago Header Logo

Connection

Lucy Godley to Hematologic Neoplasms

Back to Details
This is a "connection" page, showing publications Lucy Godley has written about Hematologic Neoplasms.
Lucy Godley
Connection Strength
11.444
Hematologic Neoplasms
  1. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023 02 28; 7(4):549-554.
    View in: PubMed
    Score: 0.698
  2. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Curr Hematol Malig Rep. 2022 08; 17(4):94-104.
    View in: PubMed
    Score: 0.664
  3. A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. Genet Med. 2022 04; 24(4):931-954.
    View in: PubMed
    Score: 0.646
  4. Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology. JCO Precis Oncol. 2021 11; 5:107-122.
    View in: PubMed
    Score: 0.637
  5. Germline predisposition to hematopoietic malignancies. Hum Mol Genet. 2021 10 01; 30(20):R225-R235.
    View in: PubMed
    Score: 0.633
  6. Anticipation in hematopoietic malignancies: biology, bias, or both? Leuk Lymphoma. 2021 12; 62(13):3070-3072.
    View in: PubMed
    Score: 0.628
  7. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. Br J Haematol. 2021 08; 194(4):663-676.
    View in: PubMed
    Score: 0.598
  8. Identifying potential germline variants from sequencing hematopoietic malignancies. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):219-227.
    View in: PubMed
    Score: 0.598
  9. Identifying potential germline variants from sequencing hematopoietic malignancies. Blood. 2020 11 26; 136(22):2498-2506.
    View in: PubMed
    Score: 0.597
  10. Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Adv. 2020 10 27; 4(20):5269-5284.
    View in: PubMed
    Score: 0.593
  11. Identifying patients with genetic predisposition to acute myeloid leukemia. Best Pract Res Clin Haematol. 2018 12; 31(4):373-378.
    View in: PubMed
    Score: 0.513
  12. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017 07 27; 130(4):424-432.
    View in: PubMed
    Score: 0.469
  13. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016 10 06; 128(14):1800-1813.
    View in: PubMed
    Score: 0.442
  14. New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. Immunol Rev. 2015 Jan; 263(1):36-49.
    View in: PubMed
    Score: 0.396
  15. Perspectives and future directions for epigenetics in hematology. Blood. 2013 Jun 27; 121(26):5131-7.
    View in: PubMed
    Score: 0.354
  16. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin Hematol. 2013 Jan; 50(1):61-9.
    View in: PubMed
    Score: 0.345
  17. HMGA2 levels in CML: reflective of miRNA gene regulation in a hematopoietic tumor? Leuk Lymphoma. 2007 Oct; 48(10):1898-9.
    View in: PubMed
    Score: 0.240
  18. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007 Sep; 48(9):1676-95.
    View in: PubMed
    Score: 0.238
  19. Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions. Cancer Discov. 2024 Mar 01; 14(3):396-405.
    View in: PubMed
    Score: 0.187
  20. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2024 Mar; 30(3):255-267.
    View in: PubMed
    Score: 0.183
  21. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023 10 24; 7(20):6092-6107.
    View in: PubMed
    Score: 0.183
  22. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.171
  23. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.169
  24. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 11; 35(11):3245-3256.
    View in: PubMed
    Score: 0.153
  25. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genet Med. 2021 01; 23(1):211-214.
    View in: PubMed
    Score: 0.146
  26. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018 01 23; 2(2):146-150.
    View in: PubMed
    Score: 0.123
  27. Recognition of familial myeloid neoplasia in adults. Semin Hematol. 2017 04; 54(2):60-68.
    View in: PubMed
    Score: 0.116
  28. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2.
    View in: PubMed
    Score: 0.109
  29. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.107
  30. Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood. 2016 Jan 21; 127(3):310-3.
    View in: PubMed
    Score: 0.106
  31. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015 Feb; 47(2):180-5.
    View in: PubMed
    Score: 0.099
  32. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.099
  33. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
    View in: PubMed
    Score: 0.074
  34. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805.
    View in: PubMed
    Score: 0.060
  35. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9.
    View in: PubMed
    Score: 0.022
  36. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
    View in: PubMed
    Score: 0.020
  37. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.016
  38. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.